Customized cationic nanoemulsions loading triamcinolone acetonide for corneal neovascularization secondary to inflammatory processes

Fernandes, Ana R.; Vidal, Lorena B; Santos, Tiago dos; Granja, Pedro L.; Silva, Amélia M.; García, María L.; Souto, Eliana B.

doi:10.1016/j.ijpharm.2022.121938

Cited by 11 publications

(6 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are also safe, show no local side effects, and, because of the increased residence time at the administration site, the therapeutic benefits are enhanced The main goal of ocular drug delivery is the development of a safe and effective system that delivers the drug on-site, which allows for an increase in the drug bioavailability [47,49]. Some of these new pharmaceutical ophthalmic formulations are in situ gels, different types of nanoparticles, liposomes, nanosuspensions, microemulsions, iontophoresis, and ocular inserts [15,16,50,51]. Nanotechnology-based nanomedicines allow an increase in the residence time, the solubility of lipophilic drugs in an aqueous medium, and the bioavailability and pharmacokinetic properties by enhancing drug penetration in eye barriers [52][53][54][55][56].…”

Section: Lipid Nanoparticlesmentioning

confidence: 99%

Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

Ana

Gliszczyńska

García

et al. 2023

JPM

Self Cite

View full text Add to dashboard Cite

Oxidation of lipids and lipoproteins contributes to inflammation processes that promote the development of eye diseases. This is a consequence of metabolism dysregulation; for instance, that of the dysfunctional peroxisomal lipid metabolism. Dysfunction of lipid peroxidation is a critical factor in oxidative stress that causes ROS-induced cell damage. Targeting the lipid metabolism to treat ocular diseases is an interesting and effective approach that is now being considered. Indeed, among ocular structures, retina is a fundamental tissue that shows high metabolism. Lipids and glucose are fuel substrates for photoreceptor mitochondria; therefore, retina is rich in lipids, especially phospholipids and cholesterol. The imbalance in cholesterol homeostasis and lipid accumulation in the human Bruch’s membrane are processes related to ocular diseases, such as AMD. In fact, preclinical tests are being performed in mice models with AMD, making this area a promising field. Nanotechnology, on the other hand, offers the opportunity to develop site-specific drug delivery systems to ocular tissues for the treatment of eye diseases. Specially, biodegradable nanoparticles constitute an interesting approach to treating metabolic eye-related pathologies. Among several drug delivery systems, lipid nanoparticles show attractive properties, e.g., no toxicological risk, easy scale-up and increased bioavailability of the loaded active compounds. This review analyses the mechanisms involved in ocular dyslipidemia, as well as their ocular manifestations. Moreover, active compounds as well as drug delivery systems which aim to target retinal lipid metabolism-related diseases are thoroughly discussed.

show abstract

Section: Lipid Nanoparticlesmentioning

confidence: 99%

Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

Ana

Gliszczyńska

García

et al. 2023

JPM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Loading TA into cationic nanoemulsion increased corneal penetration and bioavailability of TA with about 60% release of initial TA in 180 min following administration. Oil-in-water nanoemulsion composed of soybean oil, Tween 80, DABCO, glycerol, poloxamer 188, and water showed no neovascularization and no irritation 24 h after administration on chicken membranes and the rabbit model [ 43 ]. Further studies showed that the nanoemulsion resulted in an approximately 1.5-fold decreased vascular endothelial growth factor (VEGF) secretion and tumor necrosis factor alpha (TNF-α) cytokine production compared to control cells in an AMD model [ 44 ].…”

Section: Topical Nano-formulations For Ocular Drug Deliverymentioning

confidence: 99%

Application of Convergent Science and Technology toward Ocular Disease Treatment

et al. 2023

View full text Add to dashboard Cite

Eyes are one of the main critical organs of the body that provide our brain with the most information about the surrounding environment. Disturbance in the activity of this informational organ, resulting from different ocular diseases, could affect the quality of life, so finding appropriate methods for treating ocular disease has attracted lots of attention. This is especially due to the ineffectiveness of the conventional therapeutic method to deliver drugs into the interior parts of the eye, and the also presence of barriers such as tear film, blood-ocular, and blood-retina barriers. Recently, some novel techniques, such as different types of contact lenses, micro and nanoneedles and in situ gels, have been introduced which can overcome the previously mentioned barriers. These novel techniques could enhance the bioavailability of therapeutic components inside the eyes, deliver them to the posterior side of the eyes, release them in a controlled manner, and reduce the side effects of previous methods (such as eye drops). Accordingly, this review paper aims to summarize some of the evidence on the effectiveness of these new techniques for treating ocular disease, their preclinical and clinical progression, current limitations, and future perspectives.

show abstract

“…First, the drug on the surface is released rapidly (burst effect), followed by a slower and more prolonged release of the drug contained within the nanoparticle. These systems can also increase the residence time in ocular tissues, they facilitate increased bioavailability, prolonged therapeutic effect, and decreased frequency of drug administration for effective treatment of chronic ocular diseases [ 76 , 95 ]. Among these, polymeric and lipid biodegradable nanoparticles have been proposed as a promising approach in the management of retinal diseases [ 96 , 97 , 98 , 99 , 100 ].…”

Section: Drug Delivery Systems Proposed For Amdmentioning

confidence: 99%

Therapeutic Approaches for Age-Related Macular Degeneration

Galindo

Blanco-Llamero

Ana

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Damage to the retinal pigment epithelium, Bruch’s membrane and/or tissues underlying macula is known to increase the risk of age-related macular degeneration (AMD). AMD is commonly categorized in two distinct types, namely, the nonexudative (dry form) and the exudative (wet form). Currently, there is no ideal treatment available for AMD. Recommended standard treatments are based on the use of vascular endothelial growth factor (VEGF), with the disadvantage of requiring repeated intravitreal injections which hinder patient’s compliance to the therapy. In recent years, several synthetic and natural active compounds have been proposed as innovative therapeutic strategies against this disease. There is a growing interest in the development of formulations based on nanotechnology because of its important role in the management of posterior eye segment disorders, without the use of intravitreal injections, and furthermore, with the potential to prolong drug release and thus reduce adverse effects. In the same way, 3D bioprinting constitutes an alternative to regeneration therapies for the human retina to restore its functions. The application of 3D bioprinting may change the current and future perspectives of the treatment of patients with AMD, especially those who do not respond to conventional treatment. To monitor the progress of AMD treatment and disease, retinal images are used. In this work, we revised the recent challenges encountered in the treatment of different forms of AMD, innovative nanoformulations, 3D bioprinting, and techniques to monitor the progress.

show abstract

Customized cationic nanoemulsions loading triamcinolone acetonide for corneal neovascularization secondary to inflammatory processes

Cited by 11 publications

References 85 publications

Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

Application of Convergent Science and Technology toward Ocular Disease Treatment

Therapeutic Approaches for Age-Related Macular Degeneration

Contact Info

Product

Resources

About